Cellectar Biosciences

Better Therapy Through Targeted Delivery

    Latest Cellectar News

Phospholipid Drug Conjugates (PDCs)
for Targeted Delivery of Oncologic Payloads

Corporate Presentation

Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar’s PDC platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar’s PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging.

macbook-pro-cropped-right

Cellectar Biosciences

Cellectar Biosciences

December 1, 2015

We are leveraging our industry-leading PDC technology platform, and focusing our resources on oncology therapeutics in areas of unmet medical and clinical need.

Meet Our Team

PDC Delivery Platform

PDC Delivery Platform

December 1, 2015

Cellectar’s PDC platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers and cancer stem cells.